Nicox S.A.
ALCOX.PADrugs in Pipeline
10
Phase 3 Programs
7
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
NCX 470 0.1%
Open Angle Glaucoma
NCX 470
Glaucoma, Open-Angle
Naproxcinod 375 mg bid
Osteoarthritis
Naproxcinod
Osteoarthritis
Naproxcinod 375 mg
Osteoarthritis
AC-170 0.24%
Healthy Subjects
NCX 470 0.065% (initial phase of trial)
Open Angle Glaucoma
NCX-4016
Intermittent Claudication
NCX 4251
Blepharitis
Fluticasone Propionate
Blepharitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NCX 470 0.1% | Phase 3 | Open Angle Glaucoma | - | - |
NCX 470 | Phase 3 | Glaucoma, Open-Angle | - | - |
Naproxcinod 375 mg bid | Phase 3 | Osteoarthritis | - | - |
Naproxcinod | Phase 3 | Osteoarthritis | - | - |
Naproxcinod 375 mg | Phase 3 | Osteoarthritis | - | - |
AC-170 0.24% | Phase 3 | Healthy Subjects | - | - |
NCX 470 0.065% (initial phase of trial) | Phase 3 | Open Angle Glaucoma | - | - |
NCX-4016 | Phase 2 | Intermittent Claudication | - | - |
NCX 4251 | Phase 2 | Blepharitis | - | - |
Fluticasone Propionate | Phase 2 | Blepharitis | - | - |
Frequently asked questions
What is in Nicox S.A.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in Nicox S.A.'s (ALCOX.PA) pipeline across Phase 3, Phase 2. Its lead program is NCX 470 0.1% (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nicox S.A.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Nicox S.A. (ALCOX.PA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALCOX.PA biotech catalysts?→
Add ALCOX.PA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nicox S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.